Pegylated interferons Lambda-1a and alfa-2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells

Journal of Viral Hepatitis

Volumn 21, Issue 6, 2014, Pages

  Freeman, J ^a   Baglino, S ^b   Friborg, J ^c   Kraft, Z ^a   Gray, T ^a   Hill, M ^a   McPhee, F ^c   Hillson, J ^a   Lopez Talavera, J C ^c   Wind Rotolo, M ^b  

^a ZYMOGENETICS INC   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

EMERGE; HCV; interferon receptors; interferon lambda; interferon stimulated genes; side effects

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CXCL11 CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INTERFERON; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 28 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; ISG15 UBIQUITIN LIKE MODIFIER; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYXOVIRUS RESISTANCE PROTEIN; OMEGA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON LAMBDA; UBIQUITIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; EX VIVO STUDY; GENE EXPRESSION; GENE INDUCTION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VIVO STUDY; LIVER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RNA TRANSCRIPTION; BLOOD; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION PROFILING; IMMUNOLOGY; MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS);

ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84900856288     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12243     Document Type: Article

References (25)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB,. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
2. Reddy KR, Nelson DR, Zeuzem S,. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009; 50: 402-411.
3. Food and Drug Administration. PEGASYS (peginterferon alfa-2a) label. 2002. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2002/ pegihof120302LB.pdf (accessed 22 August 2012).
4. Food and Drug Administration. Copegus (ribavirin) label. 2012.
5. Domanski P, Colamonici OR,. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev 1996; 7: 143-151. (Pubitemid 27198073)
6. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE,. Interferon lambda as a potential new therapeutic for hepatitis C. Ann N Y Acad Sci 2009; 1182: 80-87.
7. Muir AJ, Shiffman ML, Zaman A, et al,. Phase 1B study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52: 822-832.
8. Donnelly RP, Dickensheets H, O'Brien TR,. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol 2011; 32: 443-450.
9. Kotenko SV, Gallagher G, Baurin VV, et al,. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77. (Pubitemid 36109115)
10. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC,. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269-32274. (Pubitemid 39014676)
11. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R,. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749-7758. (Pubitemid 47047861)
12. Ank N, Paludan SR,. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 2009; 35: 82-87.
13. Byrnes-Blake KA, Pederson S, Klucher KM, et al,. Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. J Interferon Cytokine Res 2012; 2: 198-206.
14. Doyle SE, Schreckhise H, Khuu-Duong K, et al,. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906. (Pubitemid 46489554)
15. Sommereyns C, Paul S, Staeheli P, Michiels T,. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
16. Marcello T, Grakoui A, Barba-Spaeth G, et al,. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898. (Pubitemid 44958521)
17. Maher SG, Sheikh F, Scarzello AJ, et al,. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-1115.
18. Sheppard P, Kindsvogel W, Xu W, et al,. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68. (Pubitemid 36104710)
19. Zeuzem S, Arora S, Bacon B, et al,. Pegylated interferon-lambda (pegIFN-λ) shows superior viral response with improved safety and tolerability versus pegIFN-α-2a in HCV patients (G1/2/3/4): EMERGE phase IIb through week 12 [Abstract]. J Hepatol 2011; 54: S538-S539.
20. Muir AJ, Srinivasan S, Sapra S, Dimitrova D, Hillson JL, Lopez-Talavera JC,. Peginterferon lambda-1a is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus infection, compared to peginterferon alfa-2a [abstract]. Hepatology 2012; 56 (Suppl): 578A-579A.
21. Witte K, Gruetz G, Volk HD, et al,. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10: 702-714.
22. Lasfar A, Lewis-Antes A, Smirnov SV, et al,. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66: 4468-4477.
23. Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP,. Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol 2013; 93: 377-385.
24. Diegelmann J, Beigel F, Zitzmann K, et al,. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE 2010; 5: e15200.
25. Kohli A, Zhang X, Yang J, et al,. Distinct and overlapping genomic profiles and antiviral effects of Interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cells. J Viral Hepat 2012; 19: 843-853.